Bibliography
- Del Prato S, Barnett AH, Huisman H, Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
- Morrish NJ, Wang SL, Stevens LK, Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21
- Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971 – 1993. Diabetes Care 1998;21:1138-45
- Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78
- Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta™ (linagliptin) prescribing information. Ridgefield, CT. 2011. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf [Last accessed 19 May 2011]
- Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;CD006739
- Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84
- Graefe-Mody EU, Padula S, Ring A, Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
- Friedrich C, Emser A, Woerle HJ, Graefe-Mody EU. Renal impairment has no relevant effect on long-term exposure of linagliptin in patients with type 2 diabetes mellitus. Presented at the 71st Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, 24 – 28 June 2011
- Pozzilli P, Leslie RD, Chan J, The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-44
- Ismail-Beigi F, Moghissi E, Tiktin M, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-9